PET/CT staging of Hodgkin lymphoma in no need of routine BMB

11/14/2012 | DoctorsLounge.com

Routine bone marrow biopsy did not have a significant effect on treatment management in patients with treatment-naive Hodgkin lymphoma staged with 18F-FDG-PET/CT, according to a study in the Journal of Clinical Oncology. "The added diagnostic value from routine BMB was minimal, and positive BMB findings implied upstaging in only five patients from stage III to stage IV disease of a total of 454 included patients," researchers said.

View Full Article in:

DoctorsLounge.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX